Pharmacokinetics, safety, and tolerability of inhaled remdesivir in healthy participants
Clinical and Translational Science · 2023-11 · 16 (11) · 2276-2288
DOI: 10.1111/cts.13627 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Translational Science, online erschienen am 25.09.2023. Verfasst von Rita Humeniuk und 15 weiteren Autor:innen. Beteiligte Einrichtung: Gilead Sciences, Inc., Foster City, California, USA. Hauptthemen laut MEDLINE: Alanine. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Intravenous remdesivir (RDV) is US Food and Drug Administration–approved for hospitalized and nonhospitalized individuals with coronavirus disease 2019. RDV undergoes intracellular metabolic activation to form the active triphosphate, GS‐443902, and other metabolites. Alternative administration routes, including localized pulmonary delivery, can lower systemic exposure and maximize exposure at the site of action. This study evaluated the pharmacokinetics (PK) and safety of inhaled RDV in healthy adults. This phase Ia, randomized, placebo‐controlled study evaluated inhaled RDV in healthy participants randomized 4:1 to receive RDV or placebo as single doses (4 cohorts) or multiple once‐daily doses (3 cohorts). Doses in cohorts 1–6 were administered as an aerosolized solution for inhalation through a sealed facemask; doses in cohort 7 were administered as an aerosolized solution for inhalation through a mouthpiece. Safety was assessed throughout the study. Seventy‐two participants were enrolled (inhaled RDV, n = 58 and placebo, n = 14). Following single RDV doses, RDV, GS‐704277, and GS‐441524 plasma PK parameters indicated dose‐proportional increases in area under the concentration‐time curve (AUC) extrapolated to infinite time, AUC from time zero to last quantifiable concentration, and maximum observed concentration. Analyte plasma concentrations after multiple RDV doses were consistent with those for single‐dose RDV. Analyte plasma exposures were lower when RDV was administered with a mouthpiece versus a sealed facemask. The most common adverse events included nausea, dizziness, and cough. Single‐ and multiple‐dose inhaled RDV exhibited linear and dose‐proportional plasma PK. Administration of RDV via inhalation was generally safe and well‐tolerated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Gilead Sciences, Inc., Foster City, California, USA.
- ICON plc, Salt Lake City, Utah, USA.
ORCID-Profile: Rita Humeniuk, Matthew Johnston, Helen Winter, Sandhya Girish
Zitieren
APA
Humeniuk, R., Juneja, K., Chen, S., Ellis, S., Anoshchenko, O., Xiao, D., Share, A., Johnston, M., Davies, S., DeZure, A., Llewellyn, J., Osinusi, A., Winter, H., Girish, S., Palaparthy, R., & Dresser, M. (2023). Pharmacokinetics, safety, and tolerability of inhaled remdesivir in healthy participants. Clinical and Translational Science, 16(11), 2276-2288. https://doi.org/10.1111/cts.13627
Vancouver
Humeniuk R, Juneja K, Chen S, Ellis S, Anoshchenko O, Xiao D, et al. Pharmacokinetics, safety, and tolerability of inhaled remdesivir in healthy participants. Clinical and Translational Science. 2023;16(11):2276-2288. doi:10.1111/cts.13627
BibTeX
@article{Humeniuk2023,
author = {Humeniuk, Rita and Juneja, Kavita and Chen, Shuguang and Ellis, Scott and Anoshchenko, Olena and Xiao, Deqing and Share, Aaron and Johnston, Matthew and Davies, Santosh and DeZure, Adam and Llewellyn, Joe and Osinusi, Anu and Winter, Helen and Girish, Sandhya and Palaparthy, Ramesh and Dresser, Mark},
title = {Pharmacokinetics, safety, and tolerability of inhaled remdesivir in healthy participants},
journal = {Clinical and Translational Science},
year = {2023},
volume = {16},
number = {11},
pages = {2276--2288},
doi = {10.1111/cts.13627}
}
EUVIMED